YARW · YARROW BIOSCIENCE INC

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

40 10 th Avenue, New York, NY, 10014, United States
Biotechnology
Healthcare

Market Cap

212.2M

52 Wk Range

$12.38 - $46.95

Previous Close

$13.93

Open

$13.93

Volume

135,067

Day Range

$13.53 - $14.89

Enterprise Value

129.2M

Cash

22.93M

Avg Qtr Burn

N/A

Insider Ownership

2.02%

Institutional Own.

46.58%

Qtr Updated

Jun 30th 2026